Joshua M. Murray
CORCEPT THERAPEUTICSAbout Joshua M. Murray
Joshua M. Murray, age 41, has served on Corcept’s board since June 2021. He is an independent director and an Audit Committee member designated as an “audit committee financial expert.” Murray is currently Chief Financial Officer and Head of Strategy at Orca Bio and holds an A.B. in History and Economics from Harvard College. Since May 2024, he has also served on Beyond Meat’s board of directors .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Goldman Sachs | Managing Director, Investment Banking Division | 15 years; service through April 2021 | Advised biotechnology and life sciences companies |
External Roles
| Organization | Role | Start Date | Notes |
|---|---|---|---|
| Orca Bio (private) | Chief Financial Officer and Head of Strategy | Current | Operational and finance leadership |
| Beyond Meat (public) | Director | May 2024 | Public-company board experience |
Board Governance
| Item | Detail |
|---|---|
| Independence | Board determined Murray is independent under Nasdaq rules |
| Committee Memberships | Audit Committee member (Chair: Gregg Alton) |
| Financial Expert | Designated “audit committee financial expert” under Item 407(d)(5) |
| Attendance | Each director attended ≥75% of Board and committee meetings in 2024 |
| 2024 Meeting Cadence | Board: 4; Audit Committee: 5; Compensation Committee: 1; Independent director executive sessions: 4 |
Fixed Compensation
| Component | Amount (USD) | 2024 Notes |
|---|---|---|
| Annual Director Retainer | $50,000 | Standard non‑employee director fee |
| Audit Committee Member Fee | $12,500 | Member fee (Chair receives $25,000) |
| Total Cash Fees (2024) | $62,500 | Reported for Murray |
| Director Compensation Limit (Continuing) | $1,500,000 | Annual cap approved April 2024 (cash + equity) |
| Director Compensation Limit (New Director, Year 1) | $2,000,000 | Annual cap approved April 2024 (cash + equity) |
Performance Compensation
| Award | Grant Size (shares) | Grant Timing | Grant Date Fair Value (USD) | Vesting | Outstanding Options (12/31/2024) |
|---|---|---|---|---|---|
| Annual Director Option (2024) | 30,000 | Granted at 2024 annual meeting | $516,410 | 12 equal monthly installments from grant date | 140,000 |
Notes: Director equity awards vest time‑based; no disclosed performance metrics tied to director equity. Company prohibits hedging and pledging of company securities by directors .
Other Directorships & Interlocks
| Company | Role | Overlap/Interlock | Related-Party Exposure |
|---|---|---|---|
| Beyond Meat | Director (May 2024–present) | None disclosed with Corcept customers/suppliers | Company reports no related‑party transactions since Jan 1, 2024 (other than standard director/executive compensation) |
Compensation Committee Interlocks: Corcept disclosed no compensation committee interlocks or insider participation for 2024 (committee members were Mahoney, Alton, Baker, Swisher; none officers) .
Expertise & Qualifications
- Finance and capital markets expertise (former Goldman Sachs MD in biotech/life sciences) .
- Current operating role (CFO & Head of Strategy at Orca Bio) .
- Audit committee financial expert designation signals depth in accounting/controls .
- Education: A.B. in History & Economics, Harvard College .
Equity Ownership
| Metric | Amount | As-of Date |
|---|---|---|
| Beneficial Ownership (shares) | 138,750 | April 17, 2025 (includes shares acquirable via options within 60 days) |
| Ownership % of Outstanding | <1% | April 17, 2025 (106,044,683 shares outstanding) |
| Options Outstanding (director) | 140,000 | December 31, 2024 |
Policy signals: Hedging and pledging by directors prohibited under insider trading policy .
Governance Assessment
- Positive signals: Independent status; Audit Committee member and “financial expert” designation; 2024 attendance at or above 75% across Board/committees; robust Audit Committee activity (5 meetings); and prohibition on hedging/pledging, reinforcing alignment .
- Compensation alignment: Cash fees reflect role (retainer + Audit member fee) and equity option grants with time‑based vesting; total reported director compensation for Murray in 2024 was $578,910 (cash $62,500; option grant date fair value $516,410) .
- Conflicts/related-party: No related-party transactions disclosed since Jan 1, 2024; Compensation Committee had no interlocks or insider participation in 2024 .
- Shareholder support context: 98% approval of NEO compensation at 2024 annual meeting (general governance sentiment) .
- Watch items: Dual responsibilities (CFO at Orca Bio and director/Audit Committee member at Corcept) merit monitoring for time commitments, though no attendance or engagement concerns disclosed; no director-specific severance or CoC acceleration terms disclosed for Murray (only Chairman Wilson has a CoC vesting provision) .
RED FLAGS: None disclosed for Murray regarding related‑party transactions, hedging/pledging, or low attendance; no stock pledging and no related‑party exposure reported .